A phase 1b multicenter study of TAS-102 in combination with irinotecan in patients with advanced recurrent or unresectable gastric and gastroesophageal adenocarcinoma after at least one line of treatment with a fluoropyrimidine and platinum-containing regimen
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A phase 1b multicenter study of TAS-102 in combination with irinotecan in patients with advanced recurrent or unresectable gastric and gastroesophageal adenocarcinoma after at least one line of treatment with a fluoropyrimidine and platinum-containing regimen
Authors
Keywords
-
Journal
MEDICAL ONCOLOGY
Volume 39, Issue 5, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-05-23
DOI
10.1007/s12032-022-01698-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
- (2021) Ronan J. Kelly et al. NEW ENGLAND JOURNAL OF MEDICINE
- The TRUSTY study: A randomized phase 2/3 study of trifluridine/tipiracil plus bevacizumab versus irinotecan and fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer.
- (2021) Yasutoshi Kuboki et al. JOURNAL OF CLINICAL ONCOLOGY
- First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
- (2021) Yelena Y Janjigian et al. LANCET
- Phase I Study of Trifluridine/Tipiracil Plus Irinotecan and Bevacizumab in Advanced Gastrointestinal Tumors
- (2020) Anna M. Varghese et al. CLINICAL CANCER RESEARCH
- VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): An Open Label Randomized Controlled Phase-2-Study
- (2020) Elizabeth Smyth et al. Frontiers in Oncology
- FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel: Results from the phase II RAMIRIS Study of the AIO.
- (2020) Sylvie Lorenzen et al. JOURNAL OF CLINICAL ONCOLOGY
- The prognostic value of HRD mutations in liver cancer.
- (2020) Jinzhang Chen et al. JOURNAL OF CLINICAL ONCOLOGY
- First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial
- (2020) Yelena Y Janjigian et al. LANCET ONCOLOGY
- Impact and Diagnostic Gaps of Comprehensive Genomic Profiling in Real-World Clinical Practice
- (2020) Aditi P. Singh et al. Cancers
- P-38 KEYNOTE-859: A randomized, double-blind, placebo-controlled phase 3 trial of first-line pembrolizumab plus chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma
- (2020) J. Tabernero et al. ANNALS OF ONCOLOGY
- Efficacy and Prognostic Factors for PARP Inhibitors in Patients With Ovarian Cancer
- (2020) Xuan-zhang Huang et al. Frontiers in Oncology
- Peritoneal carcinomatosis in gastric cancer: Are Hispanics at higher risk?
- (2020) Audrey H. Choi et al. JOURNAL OF SURGICAL ONCOLOGY
- Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
- (2020) Thierry André et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase II study of TAS-102 in combination with ramucirumab in advanced, refractory gastric or gastroesophageal junction (GEJ) adenocarcinoma.
- (2019) Rutika Mehta et al. JOURNAL OF CLINICAL ONCOLOGY
- KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer (mG/GEJC): A double-blind, randomized, placebo-controlled phase 3 study.
- (2019) Yelena Yuriy Janjigian et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer
- (2018) Charles S. Fuchs et al. JAMA Oncology
- Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2018) Kohei Shitara et al. LANCET ONCOLOGY
- Initial Report of Second‐Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi‐Institutional Retrospective Analysis
- (2018) Samuel J. Klempner et al. ONCOLOGIST
- A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials
- (2016) G Montalban-Bravo et al. LEUKEMIA
- Chemotherapy-induced peripheral neuropathy in patients treated with taxanes and platinum derivatives
- (2015) Marianne Ewertz et al. ACTA ONCOLOGICA
- TAS-102, a novel antitumor agent: A review of the mechanism of action
- (2015) Heinz-Josef Lenz et al. CANCER TREATMENT REVIEWS
- Crucial roles of thymidine kinase 1 and deoxyUTPase in incorporating the antineoplastic nucleosides trifluridine and 2′-deoxy-5-fluorouridine into DNA
- (2015) KAZUKI SAKAMOTO et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer
- (2015) Toshihiko Doi et al. INVESTIGATIONAL NEW DRUGS
- Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
- (2015) Robert J. Mayer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
- (2014) Hansjochen Wilke et al. LANCET ONCOLOGY
- Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2013) T. Waddell et al. ANNALS OF ONCOLOGY
- Randomized, Open-Label, Phase III Study Comparing Irinotecan With Paclitaxel in Patients With Advanced Gastric Cancer Without Severe Peritoneal Metastasis After Failure of Prior Combination Chemotherapy Using Fluoropyrimidine Plus Platinum: WJOG 4007 Trial
- (2013) Shuichi Hironaka et al. JOURNAL OF CLINICAL ONCOLOGY
- FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort
- (2013) Marcello Maugeri-Saccà et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
- (2013) Charles S Fuchs et al. LANCET
- A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy
- (2012) Sun Jin Sym et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Japanese gastric cancer treatment guidelines 2010 (ver. 3)
- (2011) Gastric Cancer
- Adenocarcinoma of the esophagogastric junction: incidence, characteristics, and treatment strategies
- (2010) Shinichi Hasegawa et al. Gastric Cancer
- Recent patterns in gastric cancer: A global overview
- (2009) Paola Bertuccio et al. INTERNATIONAL JOURNAL OF CANCER
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started